Eptifibatide: A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention

Drugs

Volumn 65, Issue 14, 2005, Pages 2009-2035

  Curran, Monique P ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Acute coronary syndromes; Eptifibatide; Percutaneous coronary intervention; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Tolerability

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRULOG; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; STREPTOKINASE; TENECTEPLASE; TICLOPIDINE; TIROFIBAN;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONCENTRATION RESPONSE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; STROKE; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VASCULAR ACCESS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; HUMANS; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 24944485002     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565140-00007     Document Type: Review

References (102)

1. American Heart Association. Heart disease and stroke statistics: 2005 update. Dallas (TX): American Heart Association, 2005
2. Gilchrist IC. Platelet glycoprotein IIb/IIIa inhibitors in percuta-neous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide. Clin Pharmacokinet 2003; 42 (8): 703-20
3. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997 Aug 18; 80 (4A): 11B-20B
4. Scarborough RM. Development of eptifibatide. Am Heart J 1999; 138: 1093-104
5. Goa KL, Noble S. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs 1999 Mar; 57 (3): 439-62
6. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997 Feb 18; 95 (4): 846-54
7. Tcheng JE, Talley JD, O'Shea JC, et al. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary interven tion (the PRIDE study). Am J Cardiol 2001 Nov 15; 88: 1097-102
8. Gilchrist IC, O'Shea JC, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 2001 Jul 24; 104: 406-11
9. Tardiff BE, Jennings LK, Harrington RA, et al. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PUR SUIT. Circulation 2001 Jul 24; 104: 399-405
10. Dalby M, Montalescot G, Bal dit Sollier C, et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel: results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol 2004 Jan 21; 43 (2): 162-8
11. Schror K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 2003 Apr; 15 (2): 71-80
12. Holmes MB, Sobel BE, Schneider DJ. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. Am J Cardiol 1999 Jul 15; 84: 203-7
13. 2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997 Sep 2; 96 (5): 1488-94
14. Moser M, Bertram U, Peter K, et al. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol 2003 Apr; 41:586-92
15. Welt FGP, Rogers SD, Zhang XB, et al. GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Cathet Cardiovasc Interv 2004 Feb; 61 (2): 185-9
16. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003 Mar 4; 107 (8): 1123-8
17. Aggarwal A, Schneider DJ, Terrien EF, et al. Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. Am J Cardiol 2003; 91 (11): 1346-9
18. 3 integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation 2001 Jul 31; 104 (5): 582-7
19. Heitzer T, Ollmann I, Koke K, et al. Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease. Circulation 2003 Aug 5; 108 (5): 536-41
20. Integrilin® (eptifibatide) injection for intravenous administration: prescribing information. Cambridge (MA) and Kenil worth (NJ): Millennium Pharmaceuticals, Inc. and Schering Corporation, 2005 Jul
21. Lorenz TJ, Macdonald F, Kitt MM. Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIa. Clin Ther 1999 Jan; 21: 128-37
22. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation 1999 Jul 27; 100 (4): 437-44
23. Simon DI, Xu H, Ortlepp S, et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997 Mar; 17 (3): 528-35
24. Ibbotson T, McGavin JK, Goa KL. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs 2003; 63 (11): 1121-63
25. Kereiakes DJ, Broderick TM, Roth EM, et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 1999 Aug 15; 84: 391-5
26. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998 Aug 13; 339 (7): 436-43
27. The ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000 Dec 16; 356: 2037-44
28. Batchelor WB, Tolleson TR, Huang Y, et al. Randomized COMparison of Platelet inhibition with Abciximab, tiRofiban and Eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE Trial. Circulation 2002 Sep 17; 106: 1470-6
29. The Price Investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. Am Heart J 2001 Mar; 141: 402-9
30. Atwater BD, Roe MT, Mahaffey KW. Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection. Drugs 2005; 65 (3): 313-24
31. Lakkis N, Lakiss N, Bobek J, et al. Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited. Catheter Cardiovasc Interv 2002 Aug; 56 (4): 474-7
32. Gretler DD. Pharmacokinetic and pharmacodynamic properties of eptifibatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. Clin Ther 2003 Oct; 25 (10): 2564-74
33. Lev EI, Hasdai D, Scapa E, et al. Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation. J Am Coll Cardiol 2004 Mar 17; 43 (6): 966-71
34. Kleiman NS, Tracy RP, Talley JD, et al. Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 2000 Jan; 9 (1): 5-12
35. Kleiman NS, Klem J, Fernandes LS, et al. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J 2002 Apr; 143: 585-93
36. Saucedo JF, Aude W, Pacheco R, et al. Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (the pharmacoDynamic Evaluation of Angiomax, Clopidogrel with Or without INtegrilin [DEACON] study). Am J Cardiol 2005 Jun 15; 95 (12): 1453-6
37. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) Study. Circulation 2005 Mar 8; 111 (7): 1153-9
38. Gretler DD, Guerciolini R, Williams PJ. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin Ther 2004 Mar; 26 (3): 390-8
39. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997 May 17; 349 (9063): 1422-8
40. O'Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 2001 May 16; 285: 2468-73
41. O'Shea JC, Buller CE, Cantor WJ, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002 Feb 6; 287:618-21
42. Suleiman M, Gruberg L, Hammerman H, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention. J Invasive Cardiol 2003; 15 (6): 319-23
43. Schweiger MJ, Changezi HU, Naglieri-Prescod D, et al. Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention. Clin Ther 2003 Jan; 25: 225-34
44. Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003 Jan 21; 107: 238-44
45. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. IMPACT investigators. Circulation 1995 Apr 15; 91 (8): 2151-7
46. Kleiman NS, Lincoff AM, Flaker GC, et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. Circulation 2000 Feb 22; 101: 751-7
47. Lincoff AM, Harrington RA, Califf RM, et al. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition: insights from the Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. Circulation 2000 Sep 5; 102: 1093-100
48. Ronner E, Boersma E, Laarman GJ, et al. Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT trial. J Am Coll Cardiol 2002 Jun 19; 39 (12): 1924-9
49. Labinaz M, Kilaru R, Pieper K, et al. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the Platelet glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. Circulation 2002 Jan 22; 105: 322-7
50. Lauer MA, Houghtaling PL, Peterson JG, et al. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. Circulation 2001 Dec 4;104: 2772-7
51. Marso SP, Bhatt DL, Roe MT, et al. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. Circulation 2000 Dec 12; 102: 2952-8
52. Cohen MG, Pacchiana CM, Corbalan R, et al. Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. Am Heart J 2001 Mar; 141: 391-401
53. Akkerhuis KM, Deckers JW, Boersma E, et al. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes: results from PURSUIT. Eur Heart J 2000 Mar; 21 (5): 371-81
54. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000 Sep 27; 284 (12): 1549-58
55. Cutlip DE, Cove CJ, Irons D, et al. Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedure outcomes. Am J Cardiol 2001 Jul 1; 88: 62-4
56. Ronner E, van Kesteren HAM, Zijnen P, et al. Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction: a phase II dose escalation, randomized, double-blind study. Arterioscler Thromb Vasc Biol 2000 Sep; 20 (18): 1530-6
57. Giugliano RP, Roe MT, Harrington RA, et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) phase II angiographic trial. J Am Coll Cardiol 2003; 41: 1251-60
58. Brener SJ, Zeymer U, Adgey AAJ, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in Acute Myo-cardial Infarction (INTRO AMI) trial. J Am Coll Cardiol 2002 Feb 6; 39: 377-86
59. Rebeiz AG, Johanson P, Green CL, et al. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am J Cardiol 2005 Mar 1; 95 (5): 611-4
60. TITAN-TIMI 34, ENDURE and ADVANCE MI studies. Cambridge (MA) and Kenilworth (NJ): Millennium Pharmaceuticals, Inc. and Schering Corporation, 2005. (Data on file)
61. Plosker GL, Ibbotson T. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes. Pharmacoeconomics 2003; 21 (12): 885-912
62. Brown A, Mittmann N, Seung SJ, et al. Economic evaluation of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous intervention with stenting [online]. Available from URL: http://www.ccohta.co [Accessed 2005 Mar 13]
63. Cohen DJ, O'Shea JC, Pacchiana CM, et al. In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT trial). Am J Cardiol 2002 Jan 1; 89: 61-4
64. Cohen DJ, Cosgrove RS, Berezin RH, et al. Cost-effectiveness of eptifibatide in patients undergoing planned coronary stenting: results from the ESPRIT trial. [abstract no. 1841]. Circulation 2001 Oct 23; 104 (17 Suppl. II): II-386-7
65. Burgess BC, Hanna-Moussa S, Ramasamy K, et al. Abciximab or eptifibatide in percutaneous coronary intervention: in-hospital outcomes and costs and six-month results. Int J Angiol 2002; 11 (4): 221-4
66. McCollam PL, Foster DA, Riesmeyer JS. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Health Syst Pharm 2003 Jun 15; 60: 1251-6
67. Wong DH. Comparison of eptifibatide and abciximab with decision analysis. Am J Health Syst Pharm 2001 Aug 1; 58: 1432-6
68. Brown RE, Henderson RA, Koster D, et al. Cost effectiveness of eptifibatide in acute coronary syndromes: an economic analysis of Western European patients enrolled in the PURSUIT trial. Eur Heart J 2002 Jan; 23: 50-8
69. Brown R, Armstrong P. Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis. Can J Cardiol 2003 Feb; 19: 161-6
70. Mark DB, Harrington RA, Lincoff M, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000 Feb 1; 101: 366-71
71. Mandak JS, Blankenship JC, Gardner LH, et al. Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. J Am Coll Cardiol 1998 Jun; 31 (7): 1518-24
72. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988 Jan; 11 (1): 1-11
73. Dyke CM, Bhatia D, Lorenz TJ, et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Ann Thorac Surg 2000 Sep; 70 (3): 866-72
74. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the coronay revascularization using integrilin and single bolus enoxaparin study. J Am Coll Cardiol 2003 Jan 1; 41: 20-5
75. Brown DL. Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment. Heart 2003 May; 89: 535-7
76. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome: the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation 1999 Jun 8; 99 (22): 2892-900
77. Glaxo Group Ltd. Eptifibatide: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/ Integrilin/Integrilin.htm [Accessed 2005 Jun 20]
78. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 2005 Mar 15, 808-47
79. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002. Summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002 Oct 1; 106 (14): 1893-900
80. Popma JJ, Ohman EM, Weitz J, et al. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001 Jan; 119 Suppl. 1: 321S-36S
81. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002 Nov; 88 (5): 711-5
82. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004 Jun 29; 109 (25): 3171-5
83. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002 Jan 19; 359 (9302): 189-98
84. Hoekstra JW, Pollack CVJr, Roe MT, et al. Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. Acad Emerg Med 2002 Nov; 9 (11): 1146-55
85. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004 Nov 3; 292 (17): 2096-104
86. Hoekstra JW, Roe MT, Peterson ED, et al. Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad Emerg Med 2005 May; 12 (5): 431-8
87. Nguyen CM, Harrington RA. Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention. Am J Cardiovasc Drug 2003; 3 (6): 423-36
88. Giugliano RP, Newby LK, Harrington RA, et al. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome-study design and rationale. Am Heart J 2005 Jun; 149 (6): 994-1002
89. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998 May 21; 338 (21): 1488-97
90. PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998 May 21; 338 (21): 1498-505
91. Schömig A, Schmitt C, Dibra A, et al. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J 2005 Jul; 26 (14): 1379-84
92. Mehilli J, Kastrati A, Schühlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004 Dec 14; 110 (24): 3627-35
93. Leopold JA, Antman EM. Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda. Circulation 2005 Mar 8; 111 (9): 1097-9
94. The Synergy Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292 (1): 45-54
95. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002 May; 143 (5): 847-53
96. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004 May 1; 93 (9): 1092-6
97. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289 (7): 853-63
98. FDA. Supplemental new drug application approval letter for bivalirudin [online]. Available from URL: http://www.fda.gov [Accessed 2005 Jun 20]
99. Brouse SD, Wiesehan VG. Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors. Ann Pharmacother 2004 Nov; 38 (11): 1783-8
100. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001 Jun 16; 357 (9272): 1905-14
101. Assent-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001 Aug 25; 358 (9282): 605-13
102. CLEAR Investigators. The combined approach to lysis utilizing eptifibatide and Rt-PA (CLEAR) stroke trial, tier 1 interval safety results. Neurology 2005 Mar 22; 64 ( 6 Suppl. 1): 402